Trial · NCT04207255
Adverse events396
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 396
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Respiratory, thoracic and mediastinal disorders | Cohort 2: Opaganib With Abiraterone | 1 | 27 | 1 |
| other | COVID-19 | Respiratory, thoracic and mediastinal disorders | Cohort 3: Opaganib With Enzalutamide | 1 | 36 | 1 |
| other | COVID-19 | Respiratory, thoracic and mediastinal disorders | Cohort 1a: Opaganib With Abiraterone | 0 | 3 | 0 |
| other | COVID-19 | Respiratory, thoracic and mediastinal disorders | Cohort 1b: Opaganib With Enzalutamide | 0 | 3 | 0 |
| other | Deep vein thrombosis | Vascular disorders | Cohort 2: Opaganib With Abiraterone | 1 | 27 | 1 |
| other | Deep vein thrombosis | Vascular disorders | Cohort 3: Opaganib With Enzalutamide | 0 | 36 | 0 |
| other | Deep vein thrombosis | Vascular disorders | Cohort 1a: Opaganib With Abiraterone | 0 | 3 | 0 |
| other | Deep vein thrombosis | Vascular disorders | Cohort 1b: Opaganib With Enzalutamide | 0 | 3 | 0 |
| other | Blood bilirubin increased | Investigations | Cohort 2: Opaganib With Abiraterone | 0 | 27 | 0 |
| other | Blood bilirubin increased | Investigations | Cohort 3: Opaganib With Enzalutamide | 0 | 36 | 0 |
| other | Blood bilirubin increased | Investigations | Cohort 1a: Opaganib With Abiraterone | 1 | 3 | 1 |
| other | Blood bilirubin increased | Investigations | Cohort 1b: Opaganib With Enzalutamide | 0 | 3 | 0 |
| other | Dizziness | Nervous system disorders | Cohort 2: Opaganib With Abiraterone | 4 | 27 | 4 |
| other | Dizziness | Nervous system disorders | Cohort 3: Opaganib With Enzalutamide | 1 | 36 | 1 |
| other | Dizziness | Nervous system disorders | Cohort 1a: Opaganib With Abiraterone | 1 | 3 | 1 |
| other | Dizziness | Nervous system disorders | Cohort 1b: Opaganib With Enzalutamide | 1 | 3 | 1 |
| other | Skin abrasion | Skin and subcutaneous tissue disorders | Cohort 2: Opaganib With Abiraterone | 0 | 27 | 0 |
| other | Skin abrasion | Skin and subcutaneous tissue disorders | Cohort 3: Opaganib With Enzalutamide | 0 | 36 | 0 |
| other | Skin abrasion | Skin and subcutaneous tissue disorders | Cohort 1a: Opaganib With Abiraterone | 1 | 3 | 1 |
| other | Skin abrasion | Skin and subcutaneous tissue disorders | Cohort 1b: Opaganib With Enzalutamide | 0 | 3 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04207255/events